|
ICCVAM Nanomaterials Workgroup (NanoWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC
|
NIEHS
|
ICCVAM workgroup established to evaluate the suitability of alternative methods to assess potential toxicity of nanomaterials.
|
|
ICCVAM Public Forum
|
Meeting/ Workshop
|
FDA
|
NIEHS, NCATS
|
ICCVAM holds annual public forums to promote national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. The 2022 Public Forum was held in May.
|
|
ICCVAM Read Across Workgroup (RAWG)
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, FDA
|
NIEHS, NLM
|
ICCVAM workgroup established to build read-across capacity within member agencies, raise awareness of the state of the science, and work towards harmonization of read-across approaches.
|
|
Identification and Validation of ctDNA Quality Control Materials
|
Resource Development
|
FDA
|
NCI
|
The ctDNA Quality Control Materials project seeks to develop a set of nationally recognized standards to enable the production of suitable quality control materials for widespread use in testing for circulating tumor DNA (ctDNA).
|
|
IEEE Reporting Standards for In Vivo Neural Interface Research Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NINDS
|
The Institute of Electrical and Electronics Engineers (IEEE) Reporting Standards for In Vivo Neural Interface Research Working Group aims to improve the transparency, interpretability, reproducibility of in vivo research studies involving neural interface technology and establish rigorous standard experimental methodologies and outcome measures.
|
|
Image-guided Interventional Therapeutics
|
Research Initiative
|
FDA
|
CC, NCI
|
This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image-guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the Food and Drug Administration (FDA) Center for Devices and Radiological Health's preclinical review of device applications while meeting the primary research goal of optimizing image-guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies.
|
|
Imaging Core Unit
|
Research Initiative
|
FDA
|
NEI
|
Imaging Core Unit
|
|
Immune Responses to Influenza Vaccination
|
Research Initiative
|
FDA
|
NIAID
|
Immune Responses to Influenza Vaccination
|
|
ImmuneChip+ Area of Interest (AOI)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NIAID, NCATS
|
This working group began with BARDA DRIVe and NCATS who developed an Microphsyiological Systems (MPS) AOI resulting in BAA contracts in 2021 for immune chip development. Continuation of these interests include refining more complex MPS that incorporate the ability to study immune responses across multiple tissues. Focus includes medical counter measures against biological, radiological and chemical threats while fostering the development of interoperable systems, biosensor incorporation (TEER etc.) and MPS standardizations.
|
|
Immunology Interest Group
|
Meeting/ Workshop
|
FDA
|
NCI, NIDDK, NHLBI, NIAID, NINDS, NIEHS, CC, NIAMS, NEI, NIDCR, NICHD, NIAAA, NIMH, NHGRI, NCCIH, NIA, NIDA, NIDCD, NIGMS, NIMHD, OD/OIR
|
The National Institute of Health (NIH) Immunology Interest Group (IIG) brings together immunologists from across all NIH institutes as well as the Food and Drug Administration (FDA). The two major activities of the IIG are a Wednesday afternoon lecture series highlighting world-class immunologists and intramural immunologists and an annual workshop where up to 350 NIH/FDA immunologists get together to present their work to the community.
|